Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALS-4 in Healthy Volunteers
NCT05274802Phase 1Completed
- Sponsor
- Aptorum Group Limited
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALS-4 in Staphylococcus aureus infection (10 arms), sponsored by Aptorum Group Limited. Primary endpoint: Number of participants with Adverse Events at 28 days. Started Mar 2021; status: completed.
02
Drugs
ALS-4
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT05274802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274802.